In our research, there are 64 overlaps between drug targets and disease targets which are the important targets involved in the therapeutic mechanism of SNS, we studied 113 compounds and 64 target genes using the screening criteria and found that each bioactive compound acts on at least 1 HCC differential gene, core targets genes were PTGS2, ESR1, AR , NOS2, CCNA2 and CHEK1. This evidence concerns the gene CHEK1 and hepatocellular carcinoma.